ArticleJHEP reports : innovation in hepatology2026
Ultra-selective radiation segmentectomy for early-stage hepatocellular carcinoma.
Article in JHEP reports : innovation in hepatology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background & Aims: Radiation segmentectomy (RS) is an emerging curative-intent therapy for early-stage hepatocellular carcinoma (HCC) when resection or ablation is not feasible. In this study, we evaluated the safety, efficacy, and dosimetric correlates of ultra-selective RS, defined as glass Methods: This retrospective study included 38 patients with 42 early-stage (BCLC 0-A) HCCs treated with ultra-selective RS from December 2022 to July 2024. All treatments used glass Results: The median tumor size was 2.4 cm with a median perfused treatment volume of 66.3 cc (4.5% of total liver volume). The median administered activity was 1.36 GBq (median absorbed dose 837 Gy). Complete response (CR) was achieved in 87% (n = 33), with only one local progression. Median local progression-free survival was not reached. Among 16 tumors with explant data, 69% showed complete necrosis and 25% extensive necrosis (median 88%). Tumor D Conclusions: Ultra-selective RS is a feasible and liver-sparing therapy for early-stage HCC. Voxel-based dosimetry confirms dose-response relationships and underscores the importance of tumor coverage. Impact and implications: This study demonstrates that ultra-selective radiation segmentectomy (uRS) with glass
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.